Implantable Cardioverter-Defibrillator Use in Older Adults: Proceedings of a Hartford Change AGEnts Symposium

Circulation: Cardiovascular Quality and Outcomes

Volumn 8, Issue 4, 2015, Pages 437-446

  Kramer, Daniel B ^a,b   Matlock, Daniel D ^c   Buxton, Alfred E ^a   Goldstein, Nathan E ^d   Goodwin, Carol ^e   Green, Ariel R ^f   Kirkpatrick, James N ^g   Knoepke, Christopher ^h   Lampert, Rachel ⁱ   Mueller, Paul S ^j   Reynolds, Matthew R ^k   Spertus, John A ^l   Stevenson, Lynne W ^m   Mitchell, Susan L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Hebrew SeniorLife Institute for Aging Research   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e American Geriatrics Society   (United States)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h UNIVERSITY OF DENVER   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MAYO CLINIC   (United States)

^k HARVARD CLINICAL RESEARCH INSTITUTE   (United States)

^l SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

end of life care; ethics; health policy and outcomes research; implantable cardioverter defibrillator

Indexed keywords

CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); EPIDEMIOLOGY; GENERAL HEALTH STATUS ASSESSMENT; GERIATRIC PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MEDICAL ETHICS; META ANALYSIS (TOPIC); PATIENT CARE; PRIORITY JOURNAL; REVIEW; TERMINAL CARE; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; AGED; DEATH, SUDDEN, CARDIAC; HEART ARREST; ORGANIZATION; RETROSPECTIVE STUDY; UNITED STATES; UTILIZATION;

AGED; CONGRESSES AS TOPIC; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART ARREST; HUMANS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84937708924     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.114.001660     Document Type: Review

References (104)

1. Myerburg RJ, Reddy V, Castellanos A. Indications for implantable cardioverter-defibrillators based on evidence and judgment. J Am Coll Cardiol. 2009; 54: 747-763. doi: 10.1016/j.jacc.2009.03.078.
2. John RM, Tedrow UB, Koplan BA, Albert CM, Epstein LM, Sweeney MO, Miller AL, Michaud GF, Stevenson WG. Ventricular arrhythmias and sudden cardiac death. Lancet. 2012; 380: 1520-1529. doi: 10.1016/S0140-6736(12)61413-5.
3. Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA III, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA III, Ferguson TB Jr, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Shanker AJ, Silka MJ, Stevenson LW, Stevenson WG, Varosy PD; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Heart Rhythm Society. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2013; 61: e6-75. doi: 10.1016/j.jacc.2012.11.007.
4. Borne RT, Peterson PN, Greenlee R, Heidenreich PA, Wang Y, Curtis JP, Tzou WS, Varosy PD, Kremers MS, Masoudi FA. Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006-2010. Results from the National Cardiovascular Data Registry's Implantable Cardioverter-DefibrillatorRegistry. Circulation. 2014; 130: 845-853. doi: 10.1161/CIRCULATIONAHA.114.008653.
5. Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, Beachy J, Blum Meisnere L, Conyers del M, Reynolds MR, Heidenreich PA, Al-Khatib SM, Pina IL, Blake K, Norine Walsh M, Wilkoff BL, Shalaby A, Masoudi FA, Rumsfeld J. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013; 10: e59-e65. doi: 10.1016/j.hrthm.2013.01.035.
6. Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, Pelargonio G, Natale A. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010; 153: 592-599. doi: 10.7326/0003-4819-153-9-201011020-00009.
7. Matlock DD, Allen LA. Defibrillators, deactivation, decisions, and dying. JAMA Intern Med. 2013; 173: 375-394. doi: 10.1001/jamainternmed.2013.2130.
8. Zhan C, Baine WB, Sedrakyan A, Steiner C. Cardiac device implantation in the United States from 1997 through 2004: a population-based analysis. J Gen Intern Med. 2008; 23(suppl 1): 13-19.
9. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prystowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 1999; 341: 1882-1890. doi: 10.1056/NEJM199912163412503.
10. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, Daubert JP, Higgins SL, Brown MW, Andrews ML; Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002; 346: 877-883. doi: 10.1056/NEJMoa013474.
11. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, Domanski M, Troutman C, Anderson J, Johnson G, McNulty SE, Clapp-Channing N, Davidson-Ray LD, Fraulo ES, Fishbein DP, Luceri RM, Ip JH; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005; 352: 225-237. doi: 10.1056/NEJMoa043399.
12. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM; Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) Investigators. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004; 350: 2140-2150. doi: 10.1056/NEJMoa032423.
13. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L, Tavazzi L; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005; 352: 1539-1549. doi: 10.1056/NEJMoa050496.
14. John Camm A, Nisam S. European utilization of the implantable defibrillator: has 10 years changed the 'enigma'? Europace. 2010; 12: 1063-1069. doi: 10.1093/europace/euq282.
15. Epstein AE, Kay GN, Plumb VJ, McElderry HT, Doppalapudi H, Yamada T, Shafiroff J, Syed ZA, Shkurovich S; ACT Investigators. Implantable cardioverter-defibrillator prescription in the elderly. Heart Rhythm. 2009; 6: 1136-1143. doi: 10.1016/j.hrthm.2009.04.010.
16. Yung D, Birnie D, Dorian P, Healey JS, Simpson CS, Crystal E, Krahn AD, Khaykin Y, Cameron D, Chen Z, Lee DS. Survival after implantable cardioverter-defibrillator implantation in the elderly. Circulation. 2013; 127: 2383-2392. doi: 10.1161/CIRCULATIONAHA.113.001442.
17. Proclemer A, Ghidina M, Gregori D, Facchin D, Rebellato L, Fioretti P, Brignole M. Impact of the main implantable cardioverter-defibrillator trials in clinical practice: data from the Italian ICD Registry for the years 2005-07. Europace. 2009; 11: 465-475. doi: 10.1093/europace/eun370.
18. Sweeney MO. The implantable cardioverter-defibrillator minimalist: an approach to patient follow-up and management of implantable defibrillators. Circulation. 2012; 126: 369-377. doi: 10.1161/CIRCULATIONAHA.111.023887.
19. Matlock DD, Peterson PN, Wang Y, Curtis JP, Reynolds MR, Varosy PD, Masoudi FA. Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the national cardiovascular data registry. Arch Intern Med. 2012; 172: 634-641; discussion 641. doi: 10.1001/archinternmed.2012.394.
20. Matlock DD, Peterson PN, Heidenreich PA, Lucas FL, Malenka DJ, Wang Y, Curtis JP, Kutner JS, Fisher ES, Masoudi FA. Regional variation in the use of implantable cardioverter-defibrillators for primary prevention: results from the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2011; 4: 114-121. doi: 10.1161/CIRCOUTCOMES.110.958264.
21. Barra S, Providência R, Paiva L, Heck P, Agarwal S. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace. 2015; 17: 174-186. doi: 10.1093/europace/euu296.
22. Healey JS, Hallstrom AP, Kuck KH, Nair G, Schron EP, Roberts RS, Morillo CA, Connolly SJ. Role of the implantable defibrillator among elderly patients with a history of life-threatening ventricular arrhythmias. Eur Heart J. 2007; 28: 1746-1749. doi: 10.1093/eurheartj/ehl438.
23. Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LY, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes. 2015; 8: 179-186. doi: 10.1161/CIRCOUTCOMES.114.001306.
24. Hernandez AF, Fonarow GC, Hammill BG, Al-Khatib SM, Yancy CW, O'Connor CM, Schulman KA, Peterson ED, Curtis LH. Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. Circ Heart Fail. 2010; 3: 7-13. doi: 10.1161/CIRCHEARTFAILURE.109.884395.
25. Chan PS, Nallamothu BK, Spertus JA, Masoudi FA, Bartone C, Kereiakes DJ, Chow T. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention. Circ Cardiovasc Qual Outcomes. 2009; 2: 16-24. doi: 10.1161/CIRCOUTCOMES.108.807123.
26. Setoguchi S, Warner Stevenson L, Stewart GC, Bhatt DL, Epstein AE, Desai M, Williams LA, Chen CY. Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverterdefibrillators: cohort study of older patients with heart failure. BMJ. 2014; 348: g2866.
27. van Rees JB, Borleffs CJ, Thijssen J, de Bie MK, van Erven L, Cannegieter SC, Bax JJ, Schalij MJ. Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace. 2012; 14: 66-73. doi: 10.1093/europace/eur255.
28. Kramer DB, Kennedy KF, Noseworthy PA, Buxton AE, Josephson ME, Normand SL, Spertus JA, Zimetbaum PJ, Reynolds MR, Mitchell SL. Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR. Circ Cardiovasc Qual Outcomes. 2013; 6: 488-497. doi: 10.1161/CIRCOUTCOMES.111.000054.
29. Kramer DB, Kennedy KF, Spertus JA, Normand SL, Noseworthy PA, Buxton AE, Josephson ME, Zimetbaum PJ, Mitchell SL, Reynolds MR. Mortality risk following replacement implantable cardioverter-defibrillator implantation at end of battery life: results from the NCDR. Heart Rhythm. 2014; 11: 216-221. doi: 10.1016/j.hrthm.2013.10.046.
30. Bilchick KC, Kamath S, DiMarco JP, Stukenborg GJ. Bundle-branch block morphology and other predictors of outcome after cardiac resynchronization therapy in Medicare patients. Circulation. 2010; 122: 2022-2030. doi: 10.1161/CIRCULATIONAHA.110.956011.
31. Dodson JA, Reynolds MR, Bao H, Al-Khatib SM, Peterson ED, Kremers MS, Mirro MJ, Curtis JP; NCDR. Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014; 63: 788-796. doi: 10.1016/j.jacc.2013.09.079.
32. Tsai V, Goldstein MK, Hsia HH, Wang Y, Curtis J, Heidenreich PA; National Cardiovascular Data's ICD Registry. Influence of age on perioperative complications among patients undergoing implantable cardioverter-defibrillators for primary prevention in the United States. Circ Cardiovasc Qual Outcomes. 2011; 4: 549-556. doi: 10.1161/CIRCOUTCOMES.110.959205.
33. Reynolds MR, Cohen DJ, Kugelmass AD, Brown PP, Becker ER, Culler SD, Simon AW. The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverterdefibrillators. J Am Coll Cardiol. 2006; 47: 2493-2497. doi: 10.1016/j.jacc.2006.02.049.
34. Bilchick KC, Stukenborg GJ, Kamath S, Cheng A. Prediction of mortality in clinical practice for medicare patients undergoing defibrillator implantation for primary prevention of sudden cardiac death. J Am Coll Cardiol. 2012; 60: 1647-1655. doi: 10.1016/j.jacc.2012.07.028.
35. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, Josephson ME, Lehmann MH, Prystowsky EN; MUSTT Investigators. Limitations of ejection fraction for prediction of sudden death risk inpatients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007; 50: 1150-1157. doi: 10.1016/j.jacc.2007.04.095.
36. Goldberger JJ, Buxton AE, Cain M, Costantini O, Exner DV, Knight BP, Lloyd-Jones D, Kadish AH, Lee B, Moss A, Myerburg R, Olgin J, Passman R, Rosenbaum D, Stevenson W, Zareba W, Zipes DP. Risk stratification for arrhythmic sudden cardiac death: identifying the roadblocks. Circulation. 2011; 123: 2423-2430. doi: 10.1161/CIRCULATIONAHA.110.959734.
37. Parkash R, Stevenson WG, Epstein LM, Maisel WH. Predicting early mortality after implantable defibrillator implantation: a clinical risk score for optimal patient selection. Am Heart J. 2006; 151: 397-403. doi: 10.1016/j.ahj.2005.04.009.
38. Kraaier K, Scholten MF, Tijssen JG, Theuns DA, Jordaens LJ, Wilde AA, van Dessel PF. Early mortality in prophylactic implantable cardioverterdefibrillator recipients: development and validation of a clinical risk score. Europace. 2014; 16: 40-46. doi: 10.1093/europace/eut223.
39. Kramer DB, Friedman PA, Kallinen LM, Morrison TB, Crusan DJ, Hodge DO, Reynolds MR, Hauser RG. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm. 2012; 9: 42-46. doi: 10.1016/j. hrthm.2011.08.031.
40. Goonewardene M, Barra S, Heck P, Begley D, Fynn S, Virdee M, Grace A, Agarwal S. Cardioverter-defibrillator implantation and generator replacement in the octogenarian. Europace. 2015; 17: 409-416. doi: 10.1093/europace/euu248.
41. Kramer DB, Reynolds MR, Mitchell SL. Resynchronization: considering device-based cardiac therapy in older adults. J Am Geriatr Soc. 2013; 61: 615-621. doi: 10.1111/jgs.12174.
42. Hammill SC, Kremers MS, Stevenson LW, Heidenreich PA, Lang CM, Curtis JP, Wang Y, Berul CI, Kadish AH, Al-Khatib SM, Pina IL, Walsh MN, Mirro MJ, Lindsay BD, Reynolds MR, Pontzer K, Blum L, Masoudi F, Rumsfeld J, Brindis RG. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm. 2010; 7: 1340-1345. doi: 10.1016/j. hrthm.2010.07.015.
43. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C; REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008; 52: 1834-1843. doi: 10.1016/j.jacc.2008.08.027.
44. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, Pfeffer MA, Solomon SD, Wilber D, Zareba W; MADIT-CRT Trial Investigators. Cardiacresynchronization therapy for the prevention of heart-failure events. N Engl J Med. 2009; 361: 1329-1338. doi: 10.1056/NEJMoa0906431.
45. Tang AS, Wells GA, Talajic M, Arnold MO, Sheldon R, Connolly S, Hohnloser SH, Nichol G, Birnie DH, Sapp JL, Yee R, Healey JS, Rouleau JL; Resynchronization-Defibrillation for Ambulatory Heart Failure Trial Investigators. Cardiac-resynchronization therapy for mildto-moderate heart failure. N Engl J Med. 2010; 363: 2385-2395. doi: 10.1056/NEJMoa1009540.
46. Penn J, Goldenberg I, Moss AJ, McNitt S, Zareba W, Klein HU, Cannom DS, Solomon SD, Barsheshet A, Huang DT; MADIT-CRT Trial investigators. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011; 22: 892-897. doi: 10.1111/j.1540-8167.2011.02011.x.
47. Wells G, Parkash R, Healey JS, Talajic M, Arnold JM, Sullivan S, Peterson J, Yetisir E, Theoret-Patrick P, Luce M, Tang AS. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials. CMAJ. 2011; 183: 421-429. doi: 10.1503/cmaj.101685.
48. Bertoldi EG, Polanczyk CA, Cunha V, Ziegelmann PK, Beck-da-Silva L, Rohde LE. Mortality reduction of cardiac resynchronization and implantable cardioverter-defibrillator therapy in heart failure: an updated meta-analysis. Does recent evidence change the standard of care? J Card Fail. 2011; 17: 860-866. doi: 10.1016/j.cardfail.2011.06.372.
49. Delnoy PP, Ottervanger JP, Luttikhuis HO, Elvan A, Misier AR, Beukema WP, van Hemel NM. Clinical response of cardiac resynchronization therapy in the elderly. Am Heart J. 2008; 155: 746-751. doi: 10.1016/j. ahj.2007.11.009.
50. Höke U, Putter H, Van Der Velde ET, Schalij MJ, Delgado V, Bax JJ, Marsan NA. Left ventricular reverse remodeling, device-related adverse events, and long-term outcome after cardiac resynchronization therapy in the elderly. Circ Cardiovasc Qual Outcomes. 2014; 7: 437-444. doi: 10.1161/CIRCOUTCOMES.113.000821.
51. Bleeker GB, Schalij MJ, Molhoek SG, Boersma E, Steendijk P, van der Wall EE, Bax JJ. Comparison of effectiveness of cardiac resynchronization therapy in patients <70 versus > or =70 years of age. Am J Cardiol. 2005; 96: 420-422. doi: 10.1016/j.amjcard.2005.03.091.
52. Joseph SM, Novak E, Arnold SV, Jones PG, Khattak H, Platts AE, Dávila-Román VG, Mann DL, Spertus JA. Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail. 2013; 6: 1139-1146. doi: 10.1161/CIRCHEARTFAILURE.113.000359.
53. Flint KM, Matlock DD, Sundareswaran KS, Lindenfeld J, Spertus JA, Farrar DJ, Allen LA. Pre-operative health status and outcomes after continuous-flow left ventricular assist device implantation. J Heart Lung Transplant. 2013; 32: 1249-1254. doi: 10.1016/j.healun.2013.09.005.
54. Sauser K, Spertus JA, Pierchala L, Davis E, Pang PS. Quality of life assessment for acute heart failure patients from emergency department presentation through 30 days after discharge: a pilot study with the Kansas City Cardiomyopathy Questionnaire. J Card Fail. 2014; 20: 18-22. doi: 10.1016/j.cardfail.2013.11.010.
55. Sullivan MD, Levy WC, Russo JE, Crane B, Spertus JA. Summary health status measures in advanced heart failure: relationship to clinical variables and outcome. J Card Fail. 2007; 13: 560-568. doi: 10.1016/j. cardfail.2007.04.001.
56. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, Zajarias A, Thourani VH, Green P, Rodés-Cabau J, Beohar N, Mack MJ, Leon MB, Cohen DJ; PARTNER Investigators. Predictors of poor outcomes after transcatheter aortic valve replacement: results from the PARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation. 2014; 129: 2682-2690. doi: 10.1161/CIRCULATIONAHA.113.007477.
57. Arnold SV, Kosiborod M, Li Y, Jones PG, Yue P, Belardinelli L, Spertus JA. Comparison of the Seattle Angina Questionnaire With Daily Angina Diary in the TERISA Clinical Trial. Circ Cardiovasc Qual Outcomes. 2014; 7: 844-850. doi: 10.1161/CIRCOUTCOMES.113.000752.
58. Chan PS, Jones PG, Arnold SA, Spertus JA. Development and validation of a short version of the Seattle angina questionnaire. Circ Cardiovasc Qual Outcomes. 2014; 7: 640-647. doi: 10.1161/CIRCOUTCOMES.114.000967.
59. Mark DB, Anstrom KJ, Sun JL, Clapp-Channing NE, Tsiatis AA, Davidson-Ray L, Lee KL, Bardy GH; Sudden Cardiac Death in Heart Failure Trial Investigators. Quality of life with defibrillator therapy or amiodarone in heart failure. N Engl J Med. 2008; 359: 999-1008. doi: 10.1056/NEJMoa0706719.
60. Noyes K, Corona E, Zwanziger J, Hall WJ, Zhao H, Wang H, Moss AJ, Dick AW; Multicenter Automatic Defibrillator Implantation Trial II. Health-related quality of life consequences of implantable cardioverter defibrillators: results from MADIT II. Med Care. 2007; 45: 377-385. doi: 10.1097/01.mlr.0000257142.12600.c1.
61. Schron EB, Exner DV, Yao Q, Jenkins LS, Steinberg JS, Cook JR, Kutalek SP, Friedman PL, Bubien RS, Page RL, Powell J. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks. Circulation. 2002; 105: 589-594.
62. Namerow PB, Firth BR, Heywood GM, Windle JR, Parides MK. Quality-of-life six months after CABG surgery in patients randomized to ICD versus no ICD therapy: findings from the CABG Patch Trial. Pacing Clin Electrophysiol. 1999; 22: 1305-1313.
63. Irvine J, Dorian P, Baker B, O'Brien BJ, Roberts R, Gent M, Newman D, Connolly SJ. Quality of life in the Canadian Implantable Defibrillator Study (CIDS). Am Heart J. 2002; 144: 282-289.
64. Sears SF Jr, Conti JB. Quality of life and psychological functioning of ICD patients. Heart. 2002; 87: 488-493.
65. Dunbar SB, Dougherty CM, Sears SF, Carroll DL, Goldstein NE, Mark DB, McDaniel G, Pressler SJ, Schron E, Wang P, Zeigler VL; American Heart Association Council on Cardiovascular Nursing, Council on Clinical Cardiology, and Council on Cardiovascular Disease in the Young. Educational and psychological interventions to improve outcomes for recipients of implantable cardioverter defibrillators and their families: a scientific statement from the American Heart Association. Circulation. 2012; 126: 2146-2172. doi: 10.1161/CIR.0b013e31825d59fd.
66. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013; 62: e147-e239.
67. Lewis KB, Stacey D, Matlock DD. Making decisions about implantable cardioverter-defibrillators from implantation to end of life: an integrative review of patients' perspectives. Patient. 2014; 7: 243-260. doi: 10.1007/s40271-014-0055-2.
68. Garrick CS, Joanne RW, Parakash PP, Marc JS, Janice MC, Kimberly B, Sui WT, Mary SA, Viviane TN, Eldrin FL, Anju N, Desai AS, Michael MG, Lynne WS. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010; 16: 106-113. doi: 10.1016/j.cardfail.2009.09.003.
69. Matlock DD, Nowels CT, Masoudi FA, Sauer WH, Bekelman DB, Main DS, Kutner JS. Patient and cardiologist perceptions on decision making for implantable cardioverter-defibrillators: a qualitative study. Pacing Clin Electrophysiol. 2011; 34: 1634-1644. doi: 10.1111/j.1540-8159.2011.03237.x.
70. Hauptman PJ, Chibnall JT, Guild C, Armbrecht ES. Patient perceptions, physician communication, and the implantable cardioverterdefibrillator. JAMA Intern Med. 2013; 173: 571-577. doi: 10.1001/jamainternmed.2013.3171.
71. Caverly TJ, Al-Khatib SM, Kutner JS, Masoudi FA, Matlock DD. Patient preference in the decision to place implantable cardioverterdefibrillators. Arch Intern Med. 2012; 172: 1104-1105. doi: 10.1001/archinternmed.2012.2177.
72. Decision aids-implantable cardioverter-defibrillator (ICD). https://patientdecisionaid.Org/. Accessed May 4, 2015.
73. Stewart GC, Weintraub JR, Pratibhu PP, Semigran MJ, Camuso JM, Brooks K, Tsang SW, Anello MS, Nguyen VT, Lewis EF, Nohria A, Desai AS, Givertz MM, Stevenson LW. Patient expectations from implantable defibrillators to prevent death in heart failure. J Card Fail. 2010; 16: 106-113. doi: 10.1016/j.cardfail.2009.09.003.
74. Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Ann Intern Med. 2004; 141: 835-838.
75. Kramer DB, Kesselheim AS, Salberg L, Brock DW, Maisel WH. Ethical and legal views regarding deactivation of cardiac implantable electrical devices in patients with hypertrophic cardiomyopathy. Am J Cardiol. 2011; 107: 1071-1075.e5. doi: 10.1016/j.amjcard.2010.11.036.
76. Kirkpatrick JN, Gottlieb M, Sehgal P, Patel R, Verdino RJ. Deactivation of implantable cardioverter defibrillators in terminal illness and end of life care. Am J Cardiol. 2012; 109: 91-94. doi: 10.1016/j. amjcard.2011.08.011.
77. Kramer DB, Kesselheim AS, Brock DW, Maisel WH. Ethical and legal views of physicians regarding deactivation of cardiac implantable electrical devices: a quantitative assessment. Heart Rhythm. 2010; 7: 1537-1542. doi: 10.1016/j.hrthm.2010.07.018.
78. Buchhalter LC, Ottenberg AL, Webster TL, Swetz KM, Hayes DL, Mueller PS. Features and outcomes of patients who underwent cardiac device deactivation. JAMA Intern Med. 2014; 174: 80-85. doi: 10.1001/jamainternmed.2013.11564.
79. Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care.[see comment: summary for patients in Ann Intern Med. 2004; 141: I38; PMID: 15583220]. Ann Intern Med. 2004; 141: 835-838.
80. Mueller PS, Jenkins SM, Bramstedt KA, Hayes DL. Deactivating implanted cardiac devices in terminally ill patients: practices and attitudes. Pacing Clin Electrophysiol. 2008; 31: 560-568. doi: 10.1111/j.1540-8159.2008.01041.x.
81. Kelley AS, Reid MC, Miller DH, Fins JJ, Lachs MS. Implantable cardioverter-defibrillator deactivation at the end of life: a physician survey. Am Heart J. 2009; 157: 702-708. doi: 10.1016/j.ahj.2008.12.011.
82. Morrison LJ, Calvin AO, Nora H, Porter Storey C Jr. Managing cardiac devices near the end of life: a survey of hospice and palliative care providers. Am J Hosp Palliat Care. 2010; 27: 545-551. doi: 10.1177/1049909110373363.
83. Goldstein NE, Mehta D, Teitelbaum E, Bradley EH, Morrison RS. "It's like crossing a bridge" complexities preventing physicians from discussing deactivation of implantable defibrillators at the end of life. J Gen Intern Med. 2008; 23(suppl 1): 7-12. doi: 10.1007/s11606-007-0239-8.
84. Marinskis G, van Erven L; EHRA Scientific Initiatives Committee. Deactivation of implanted cardioverter-defibrillators at the end of life: results of the EHRA survey. Europace. 2010; 12: 1176-1177. doi: 10.1093/europace/euq272.
85. Hauptman PJ, Swindle J, Hussain Z, Biener L, Burroughs TE. Physician attitudes toward end-stage heart failure: a national survey. Am J Med. 2008; 121: 127-135. doi: 10.1016/j.amjmed.2007.08.035.
86. Kapa S, Mueller PS, Hayes DL, Asirvatham SJ. Perspectives on withdrawing pacemaker and implantable cardioverter-defibrillator therapies at end of life: results of a survey of medical and legal professionals and patients. Mayo Clin Proc. 2010; 85: 981-990. doi: 10.4065/mcp.2010.0431.
87. Lampert R, Hayes DL, Annas GJ, Farley MA, Goldstein NE, Hamilton RM, Kay GN, Kramer DB, Mueller PS, Padeletti L, Pozuelo L, Schoenfeld MH, Vardas PE, Wiegand DL, Zellner R; American College of Cardiology; American Geriatrics Society; American Academy of Hospice and Palliative Medicine; American Heart Association; European Heart Rhythm Association; Hospice and Palliative Nurses Association. HRS Expert Consensus Statement on the Management of Cardiovascular Implantable Electronic Devices (CIEDs) in patients nearing end of life or requesting withdrawal of therapy. Heart Rhythm. 2010; 7: 1008-1026. doi: 10.1016/j.hrthm.2010.04.033.
88. Mueller PS, Hook CC, Hayes DL. Ethical analysis of withdrawal of pacemaker or implantable cardioverter-defibrillator support at the end of life. Mayo Clin Proc. 2003; 78: 959-963. doi: 10.4065/78.8.959.
89. Pellegrino ED. Decisions to withdraw life-sustaining treatment: a moral algorithm. JAMA. 2000; 283: 1065-1067.
90. Zellner RA, Aulisio MP, Lewis WR. Should implantable cardioverter-defibrillators and permanent pacemakers in patients with terminal illness be deactivated? Deactivating permanent pacemaker in patients with terminalillness. Patient autonomy is paramount. Circ Arrhythm Electrophysiol. 2009; 2: 340-344; discussion 340. doi: 10.1161/CIRCEP.109.848523.
91. Sulmasy DP. Within you/without you: biotechnology, ontology, and ethics. J Gen Intern Med. 2008; 23 Suppl 1: 69-72. doi: 10.1007/s11606-007-0326-x.
92. Kramer DB, Buxton AE, Zimetbaum PJ. Time for a change - a new approach to ICD replacement. N Engl J Med. 2012; 366: 291-293. doi: 10.1056/NEJMp1111467.
93. Katritsis DG, Josephson ME. Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? Europace. 2012; 14: 787-794. doi: 10.1093/europace/eus001.
94. Parkash R, Sapp JL, Basta M, Doucette S, Thompson K, Gardner M, Gray C, Brownell B, Kidwai H, Cox J. Use of primary prevention implantable cardioverter-defibrillators in a population-based cohort is associated with a significant survival benefit. Circ Arrhythm Electrophysiol. 2012; 5: 706-713. doi: 10.1161/CIRCEP.112.970798.
95. Shah B, Hernandez AF, Liang L, Al-Khatib SM, Yancy CW, Fonarow GC, Peterson ED; Get With The Guidelines Steering Committee. Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. J Am Coll Cardiol. 2009; 53: 416-422. doi: 10.1016/j.jacc.2008.09.045.
96. Pertzov B, Novack V, Zahger D, Katz A, Amit G. Insufficient compliance with current implantable cardioverter defibrillator (ICD) therapy guidelines in post myocardial infarction patients is associated with increased mortality. Int J Cardiol. 2013; 166: 421-424. doi: 10.1016/j. ijcard.2011.10.132.
97. Al-Khatib SM, Hellkamp A, Bardy GH, Hammill S, Hall WJ, Mark DB, Anstrom KJ, Curtis J, Al-Khalidi H, Curtis LH, Heidenreich P, Peterson ED, Sanders G, Clapp-Channing N, Lee KL, Moss AJ. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013; 309: 55-62. doi: 10.1001/jama.2012.157182.
98. Stevenson LW. Heart failure with better ejection fraction: a modern diagnosis. Circulation. 2014; 129: 2364-2367. doi: 10.1161/CIRCULATIONAHA.114.010194.
99. Schneider PM, Pellegrini CN, Wang Y, Fein AS, Reynolds MR, Curtis JP, Masoudi FA, Varosy PD. Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008. Am J Cardiol. 2014; 113: 2052-2056. doi: 10.1016/j.amjcard.2014.03.049.
100. Yuhas J, Mattocks K, Gravelin L, Remetz M, Foley J, Fazio R, Lampert R. Patients' attitudes and perceptions of implantable cardioverter-defibrillators: potential barriers to appropriate primary prophylaxis. Pacing Clin Electrophysiol. 2012; 35: 1179-1187. doi: 10.1111/j.1540-8159.2012.03497.x.
101. Sepucha KR, Fowler FJ Jr, Mulley AG Jr. Policy support for patientcentered care: the need for measurable improvements in decision quality. Health Aff (Millwood). 2004; Suppl Variation: VAR54-VAR62. doi: 10.1377/hlthaff.var.54.
102. Sepucha KR, Scholl I. Measuring shared decision making: a review of constructs, measures, and opportunities for cardiovascular care. Circ Cardiovasc Qual Outcomes. 2014; 7: 620-626. doi: 10.1161/CIRCOUTCOMES.113.000350.
103. National quality forum. Priority setting for healthcare performance measurement: Addressing performance measure gaps in person-centered care and outcomes. Final report, august 15, 2014. http://www.Qualityforum.Org/publications/2014/08/priority-setting-for-healthcare-performance-measurement-addressing-performance-measure-gaps-in-person-centered-care-and-outcomes.Aspx. Accessed April 13, 2015.
104. Goldstein NE, Kalman J, Kutner JS, Fromme EK, Hutchinson MD, Lipman HI, Matlock DD, Swetz KM, Lampert R, Herasme O, Morrison RS. A study to improve communication between clinicians and patients with advanced heart failure: methods and challenges behind the working to improve discussions about defibrillator management trial. J Pain Symptom Manage. 2014; 48: 1236-1246. doi: 10.1016/j. jpainsymman.2014.03.005.